TSA-SAB co-loaded liposome self-dissolving microneedle synergistic delivery system: a breakthrough dual-drug loading strategy for multi-target therapy of hypertrophic scars

release followed Higuchi model (24 h: 68.33% TSA, 76.33% SAB) without burst release. Integrating nanocarriers with microneedles, this study provides a strategy to address multi-drug incompatibility and transdermal barriers, laying groundwork for HS therapy translation.